Wird geladen...
The TOUCH program and natalizumab: Fundamental flaw in patient protection
Many drugs have been approved by the Food and Drug Administration (FDA) since 1993 for treatment of relapsing forms of multiple sclerosis (MS). One such drug is natalizumab (Tysabri, Biogen Idec and Elan pharmaceuticals) which has enjoyed great success in the management of MS since its re-introducti...
Gespeichert in:
| Veröffentlicht in: | F1000Res |
|---|---|
| 1. Verfasser: | |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
F1000Research
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4837976/ https://ncbi.nlm.nih.gov/pubmed/27134725 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.7513.3 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|